AVRO 1330% upside potential according to this analyst!!!

AVROBIO is a clinical-stage gene therapy company to treat rare diseases following a single dose worldwide.

AVRO just released positive data on their Phase 1/2 trial testing the safety and efficacy of AVR-RD-04.

73.42% of the shares are controlled by institutional investors, which gives me a lot of trust in the company.
JPMorgan Chase and BlackRock Inc . have the largest stakes in the company with an average around $9 per share.

On 1/5/2022 Barclays brokerage Boosted the Price Target of AVRO from $6.00 to $22.00.

The stock is now at all time low: $1.65.
the MARKET CAP is only 71.978Mil
I think it can be an easy buyout at this point.

What are we waiting for?


The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.